BioSpace News Archive

Veeva Systems announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials.

Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017. Under the terms of the agreement, Shionogi

Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™) preclinical programs will be presented as an e-poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II taking place from June 22-24, 2020.

Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that, effective May 19, 2020, shares of the Corporation have been reapproved for and will recommence trading on the OTCQB Venture Market, operated by OTC Markets Group. Since February 4, 2019, shares of Kan

Teva Canada to be first company to import emergency supply of salbutamol inhalers - providing access to critically needed medication for Canadian patients

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer.

Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a $53 million Series C extension, which brings the Series C round to over $90 million.

New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.

U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases,